




PHARMACEUTICAL 2022

Skye Bioscience Inc.
Rank 395 of 475





PHARMACEUTICAL 2022

Skye Bioscience Inc.
Rank 395 of 475

The relative strengths and weaknesses of Skye Bioscience Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Skye Bioscience Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 38% points. The greatest weakness of Skye Bioscience Inc. is the variable Net Income, reducing the Economic Capital Ratio by 224% points.

The company's Economic Capital Ratio, given in the ranking table, is -407%, being 130% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	9,612
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,912
Liabilities, Non-Current	79
Other Assets	155
Other Compr. Net Income	0
Other Expenses	2.1
Other Liabilities	0
Other Net Income	-672
Property and Equipment	88
Research and Development	2,931
Revenues	0
Selling, General and Administrative Expense	4,916

Output Variable	Value in 1000 USD
Assets	9,855
Liabilities	3,991
Expenses	7,850
Stockholders Equity	5,864
Net Income	-8,522
Comprehensive Net Income	-8,522
Economic Capital Ratio	-407%

